Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rosacure is a line of topical dermocosmetic products and medical devices developed by General Topics (under the Synchroline brand) specifically for the management of skin affected by rosacea. The formulation is designed to address the primary symptoms of rosacea, including persistent redness (erythema), stinging, and burning sensations. The therapeutic effect is achieved through a combination of active ingredients: methylsulfonylmethane (MSM) provides anti-inflammatory benefits by modulating cytokine activity; silymarin acts as a potent antioxidant to protect against oxidative stress; and butylcyclohexanol serves as a TRPV1 antagonist to reduce sensory discomfort and skin reactivity. These components work synergistically to reinforce the skin barrier and mitigate the inflammatory response to environmental triggers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rosacure.